Read Time: 2 mins

Beyond Anti-VEGFs – Anti-Insulin Receptor Substrate-1 Oligonucleotides as a Novel Approach to Ocular Neovascular Disorders

Copy Link
Published Online: May 22nd 2012 European Ophthalmic Review, 2012;6(3):190 –3 DOI:
Authors: James W Bainbridge, Vanya Loroch, Eric Viaud, Claus Cursiefen
Quick Links:
Article Information

Angiogenesis is a complex process that is vital to health but is also a driving factor behind a broad range of malignant, ischaemic, inflammatory, infectious and immune disorders. For optimal efficacy and safety, therapies aimed at preventing angiogenic-mediated disorders must differentiate between healthy and pathological angiogenesis or neovascularisation. Aganirsen is an antisense oligonucleotide that inhibits the insulin receptor substrate (IRS)-1 angiogenic pathway by targeting the IRS-1 messenger RNA. To date, studies of aganirsen have focused mainly on ocular disorders because of the ability to assess non-invasively the effect of the drug on neovascularisation and to address the unmet need for effective therapies in these blinding disorders. Aganirsen (GS-101) eye drops inhibit progressive corneal neovascularisation and appear to be well tolerated. The drug may offer an alternative and/or adjunct to intraocular anti-vascular endothelial cell growth factor (VEGF) agents, which are the current reference standards to prevent neovascularisation in retinal diseases. This is because it has a different and potentially complementary mechanism of action and can be administered topically. Antisense oligonucleotides targeting IRS-1 may present a valuable new approach to control pathological angiogenesis in the eye and elsewhere.


Aganirsen (GS-101), antisense oligonucleotide, insulin receptor substrate-1, ocular disorders, topical anti-angiogenic therapy, adjunct to anti-VEGF, healthy and pathological angiogenesis


Angiogenesis and its Importance in Health and Disease
The formation of new blood vessels, commonly called ‘angiogenesis’, comprises several processes that include vasculogenesis, where stem cells or angioblasts differentiate into blood vessels and which occurs in developing, initially avascular embryos and to a certain extent in adults;1 and angiogenesis per se, where new blood vessels (especially capillaries) grow from pre-existing vessels by sprouting or branching2 and which is the prevailing mechanism in adults.3

Angiogenesis is necessary to supply tissues with nutrients and oxygen, and is an integral mechanism in many physiological processes, such as wound healing and tissue growth and repair,4 muscle development5 and ovulation.6 At the same time, disruption of the fine balance between factors that induce blood vessel formation and those that inhibit or halt the process can result in pathological angiogenesis, or neovascularisation, leading to increased formation of blood vessels that may be excessive or occur in normally avascular tissue. For example, rapid and persistent growth of new blood vessels is a hallmark of cancer, while excessive angiogenesis can provide a route of entry for inflammatory cells into sites of chronic injury (e.g. Crohn’s disease), contributes to the increased epithelial cell turnover and skin plaques in psoriasis and causes ocular diseases that can lead to blindess.7 Neovascularisation is implicated in a multitude of malignant, ischaemic, inflammatory, infectious and immune disorders.3

As angiogenesis is so vital for health, any therapeutic strategy aimed at treating angiogenic-mediated disease must discriminate between physiological and pathological angiogenesis to ensure that only neovascularisation is affected. It is also important to recognise that all angiogenic mechanisms may participate in neovascularisation to various extents in different diseases. A thorough understanding of the processes controlling angiogenesis and gaining access to as many molecular targets in the relevant regulatory pathways as possible is essential in developing an appropriate therapy.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

James W Bainbridge is a NIHR Research Professor and is supported by the NIHR Biomedical Research Centre for Ophthalmology at Moorfields and UCL. He has participated in one clinical trial workshop sponsored by Gene Signal. Claus Cursiefen and Vanya Loroch are consultants to Gene Signal. Eric Viaud is the Chief Executive Officer of Gene Signal International SA.


Claus Cursiefen, University of Cologne, Albertus-Magnus-Platz 1, 50931 Cologne, Germany. E:


The publication of this article was funded by Gene Signal.




  1. Persson AB, Buschmann IR, Vascular growth in health and disease, Front Mol Neurosci, 2011;4:14.
  2. Patan S, Vasculogenesis and angiogenesis, Cancer Treat Res, 2004;117:3–32.
  3. Carmeliet P, Mechanisms of angiogenesis and arteriogenesis, Nat Med, 2000;6(4):389–95.
  4. Li WW, Talcott KE, Zhai AW, et al., The role of therapeutic angiogenesis in tissue repair and regeneration, Adv Skin Wound Care, 2005;18:491–500.
  5. Gustafsson T, Kraus WE, Exercise-induced angiogenesisrelated growth and transcription factors in skeletal muscle, and their modification in muscle pathology, Front Biosci, 2001;1(6):D75–89.
  6. Plendl J, Angiogenesis and vascular regression in the ovary, Anat Histol Embryol, 2000;29(5):257–66.
  7. Polverini PJ, Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunites, J Dent Educ, 2002;66(8):962–75.
  8. Qazi Y, Maddula S, Ambati BK, Mediators of ocular angiogenesis, J Genet, 2009;88(4):495–515.
  9. Bachmann B, Taylor RS, Cursiefen C, The association between corneal neovascularization and visual acuity: a systematic review, Acta Ophthalmol, 2011 (Epub ahead of print).
  10. Cursiefen C, Colin J, Dana R, et al., Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable, Br J Ophthalmol, 2012;96(1):3–9.
  11. Bressler NM, Early detection and treatment of neovascular age-related macular degeneration, J Am Board Fam Pract, 2002;15(2):142–52.
  12. Bockelbrink A, Roll S, Ruether K, et al., Cataract surgery and the development or progression of age-related macular degeneration: a systematic review, Surv Ophthamol, 2008;53(4):359–67.
  13. Kempen JH, O'Colmain BJ, Leske MC, et al., The prevalence of diabetic retinopathy among adults in the United States, Arch Ophthalmol, 2004;122:552–63.
  14. Shazly TA, Latina MA, Neovascular glaucoma: etiology, diagnosis and prognosis, Semin Ophthalmol, 2009;24(2):113–21.
  15. Naumann GOH, General Opühthalmic Pathology. In: Naumann GOH, Holbach L, Kruse FE, Applied pathology for ophthalmic microsurgeons, Berlin: Springer, 2008;7–28.
  16. Setlur VJ, Parikh JG, Rao NA, Changing causes of enucleation over the past 60 years, Graefes Arch Clin Exp Ophthalmol, 2010;248(4):593–7.
  17. Gergely K, Gerinec A, Retinopathy of prematurity – epidemics, incidence, prevalence, blindness, Bratisl Lek Listy, 2010;111(9):514–7.
  18. Zin A, The increasing problem of retinopathy of prematurity, Community Eye Health, 2001;14(40):58–9.
  19. Panda A, Vanthi M, Kumar A, et al., Corneal graft rejection, Surv Ophthamol, 2007;52(4):375–95.
  20. Sellami D, Abid S, Bouaouaja G, et al., Epidemiology and risk factors for corneal graft rejection, Transplant Proc, 2007;39:2609–11.
  21. Bachmann B, Taylor RS, Cursiefen C, Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis, Ophthalmology, 2010;117(7):1300–5.
  22. Williams KA, Esterman AJ, Bartlett C, et al., How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis, Transplantation, 2006;81(6):896–901.
  23. Eye Bank Association of America, Frequently asked questions. Available at: frequently-asked-questions/ (accessed 2 June 2012).
  24. Mitchell P, A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab, Curr Med Res Opin, 2011;27(7):1465–75.
  25. Kimoto K, Kubota T, Anti-VEGF agents for ocular angiogenesis and vascular permeability, J Ophthalmol, 2012,2012:852183.
  26. Lichtlen P, Lam TT, Nork TM, et al., Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105, Invest Ophthalmol Vis Sci, 2010;51(9):4738–45.
  27. Tolentino M, Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease, Surv Ophthamol, 2011;56(2):95–113.
  28. Saint-Geniez M, Maharaj AS, Walshe TE, et al., Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors, PLoS One, 2008;3(11):e3554.
  29. Al-Mahmood S, Colin S, Farhat N, et al., Potent in vivo antiangiogenic effects of GS-101 (5- TATCCGGAGGGCTCGCCATGCTGCT-3), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1, J Pharmacol Exp Ther, 2009;329:496–504.
  30. Cloutier F, Lawrence M, Goody R, et al., Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration, Invest Ophthalmol Vis Sci, 2012;53(3):1195–203.
  31. Schellekens H, The immunogenicity of therapeutic proteins, Discov Med, 2010;9(49):560–4.
  32. Andrieu-Soler C, Berdugo M, Doat M, et al., Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis, Invest Ophthalmol Vis Sci, 2005;46:4072–8.
  33. Hos D, Regenfuss B, Bock F, et al., Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis, Invest Ophthalmol Vis Sci, 2011;52:5778–85.
  34. Cursiefen C, Bock F, Horn FK, et al., GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial, Ophthalmology, 2009;116:1630–7.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72